Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New fecal markers: recent developments and perspectives].

N Kapel1, L Barbot, J-G Gobert

  • 1Laboratoire de coprologie fonctionnelle, GH Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, F75652 Paris Cedex 13, France. nathalie.kapel@psl.ap-hop-paris.fr

Annales Pharmaceutiques Francaises
|November 20, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of Gut Biomarkers of FPIES in a Longitudinal Comparative Pediatric Study.

Allergy·2024
Same author

'A five-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae' - Author's reply.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2019
Same author

A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2019
Same author

Faecal microbiota transplantation with frozen capsules for relapsing Clostridium difficile infections: the first experience from 15 consecutive patients in France.

The Journal of hospital infection·2018
Same author

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.

Journal of Crohn's & colitis·2016
Same author

Fecal calprotectin and α1-antitrypsin dynamics in gastrointestinal GvHD.

Bone marrow transplantation·2015
Same journal

[Artificial Intelligence in the Pharmaceutical Industry: Governance, Quality, and Regulatory Challenges].

Annales pharmaceutiques francaises·2026
Same journal

No evidence of significant natural environmental exposure to arsenic for Napoleon I on the island of Saint Helena (1815-1821).

Annales pharmaceutiques francaises·2026
Same journal

EFFECTS OF GLP-1 RECEPTOR AGONISTS ON PERIODONTAL TISSUE: AN INTERDISCIPLINARY EVIDENCE MAPPING - SCOPING REVIEW.

Annales pharmaceutiques francaises·2026
Same journal

Regulatory non-compliance of parallel imported medicines in Kenya and implications for public health: Evidence from Nairobi County.

Annales pharmaceutiques francaises·2026
Same journal

Prostaglandin analogues in cosmetic products formulated for eyelash lengthening.

Annales pharmaceutiques francaises·2026
Same journal

Mechanistic and thermodynamic evaluation of sodium citrate-mediated hydrotropism for the biopharmaceutical optimization of BCS Class II drug atorvastatin calcium.

Annales pharmaceutiques francaises·2026
See all related articles

Non-invasive fecal markers are revolutionizing gastrointestinal disease screening. These tests offer accurate detection for colorectal cancer, inflammatory bowel disease, and pancreatic insufficiency, improving patient management.

Area of Science:

  • Gastroenterology
  • Biomarker Discovery
  • Diagnostic Medicine

Context:

  • Colorectal cancer screening relies heavily on fecal occult blood testing.
  • Immunological tests enhance specificity, while fecal DNA analysis offers new early detection avenues.
  • Inflammatory bowel disease diagnosis traditionally involves invasive endoscopy.

Purpose:

  • To explore the utility of non-invasive fecal markers in gastrointestinal diagnostics.
  • To highlight advancements in fecal testing for colorectal cancer, inflammatory bowel disease, and pancreatic insufficiency.
  • To assess the potential of fecal markers in disease screening and patient management.

Summary:

  • Fecal occult blood testing is a primary colorectal cancer screening method, with immunological tests improving specificity.

Related Experiment Videos

  • Fecal DNA analysis presents a novel approach for early neoplasia detection.
  • Fecal TNFalpha, calprotectin, and elastase serve as valuable non-invasive markers for inflammatory bowel disease and exocrine pancreatic insufficiency, aiding in diagnosis and disease activity assessment.

    • Impact:

    • Non-invasive fecal markers provide a less invasive and potentially more accessible alternative to traditional diagnostic methods.
    • These markers facilitate early disease detection and improved patient stratification for further investigation.
    • The development of fecal markers offers significant advancements in screening and managing a wide range of gastrointestinal conditions.